Engineered immune cells take on lupus and scleroderma
NCT ID NCT06347718
First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 35 times
Summary
This study tests a new treatment for people with lupus, scleroderma, dermatomyositis, or polymyositis. The treatment uses a patient's own immune cells, which are modified in a lab to find and attack faulty B cells that drive the disease. The goal is to control the autoimmune attack and reduce symptoms, but ongoing management may still be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universitätsklinikum Erlangen
RECRUITINGErlangen, Bavaria, 91054, Germany
Contact
Contact
Conditions
Explore the condition pages connected to this study.